Introduction {#s1}
============

Alzheimer's disease (AD) is one of the age-related cognitive decline. It is a main challenge of mental health research ([@B45]), and is clinically characterized by cognitive dysfunction, neuronal injury, and synapse loss ([@B46]). Currently, there are approximately 50 million AD patients in the world ([@B2]). Although donepezil and memantine could delay AD symptom progression, side effects have been reported. Considering the number of AD patients and corresponding societal costs, plenty of clinical research has focused on the potential benefits of natural medicines.

*Ginkgo biloba* leaves are one of the popular herbal medicines, and they are recorded in the *Chinese Pharmacopoeia* (2015 edition). *G. biloba* leaves are well known in hypertension ([@B1]), ischemic myocardium ([@B49]), and cerebral ischemia ([@B51]). Remarkably, the extract of *G. biloba* leaves (EGb) attenuates the neuronal damage in animals ([@B28]; [@B51]) and *in vitro* ([@B48]). The chemical constituents of EGb are evaluated as follows: 22%--27% of flavone glycosides, 2.8%--3.4% of Ginkgolide A, B, and C, 2.6%--3.2% of bilobalide, and less than 5 ppm of ginkgolic acid ([@B6]). Modern pharmacological studies have shown that the combination of extract of *G. biloba* and donepezil may be beneficial in the treatment of AD in rat and mice ([@B42]; [@B50]). Furthermore, Ginkgolide B, one of the major active ingredients in EGb, can inhibit the neurotoxicity induced by β-amyloid ([@B41]; [@B27]; [@B21]; [@B9]).

However, whether EGb improves cognitive function in clinical study is a controversial question. Although a few available large-scale clinical trials suggest that EGb is relatively efficacious in delaying the progress of dementia, several other trials showed negative results. The present review searches large-scale clinical studies published in databases including Pubmed, ScienceDirect, and SpringerLink before 2019, and provides an analysis in the effective on cognitive function in EGb ([**Tables 1A**](#T1a){ref-type="table"}, [**B**](#T1b){ref-type="table"}).

###### 

The negative results of clinical trials of AD with EGb.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study    Patients and gender female   Age (years) \[mean(SD)\]   Ginkgo biloba dose (mg/day)   Duration    Inclusion criteria                                                                                                                                                                                                    Outcome measures                                                                                                                                                                               Published date
  -------- ---------------------------- -------------------------- ----------------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  [@B44]   8 F                          32.0                       120; 240; 600                 One-dose    Healthy volunteers                                                                                                                                                                                                    CFF; CRT; LARS                                                                                                                                                                                 1984

  [@B38]   8 M                          27.3                       80                            2 w         Healthy volunteers                                                                                                                                                                                                    Complex choice test; battery of oculomotor and cardiorespiratory tests                                                                                                                         1985

  [@B24]   12 F                         22.0                       600                           One-dose    Healthy volunteers                                                                                                                                                                                                    CFF; CRT; LARS; long memory (p \<0.05)                                                                                                                                                         1990

  [@B43]   26 F; 24 M                   30.4                       120                           30 d        Healthy volunteers exclude head injury, intellectual developmental disability, neurological or psychiatric illness, current pregnancy, and current use of any other medication                                        Digit Symbol Substitution Test; Speed of Comprehension Test; Symbol Digit Modalities Test; Digit Span; Trail Making Test; Rey Auditory Verbal Learning Test; Inspection Time; working memory   2001

  [@B23]   15 F; 5 M                    21.2                       360                           One-dose    Healthy undergraduate volunteers exclude heavy smoker and taking illicit social drugs                                                                                                                                 Cognitive measures; memory; attention; serial subtraction tasks; subjective mood measure                                                                                                       2002

  [@B40]   18 F; 2 M                    19.9                       120; 240; 360                 One-dose    Healthy volunteers exclude taking other medication and heavy smoker                                                                                                                                                   serial subtractions; speed of attention                                                                                                                                                        2002

  [@B7]    EGb: 68 F; 11 M\             82.6\                      160; 240                      24 w        a diagnosis of uncomplicated dementia age ≥ 50 years a score ranging from 8 to 23 on the SKT score absence of depression IQ \> 80 absence serious comorbidity                                                         Syndrom Kurz Test; Clinical Global Impression-2; Nürnberger Alters Alltagsaktivitäten Skala                                                                                                    2003
           Placebo: 36 F; 8 M           82.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@B30]   EGb: 11 F; 10 M\             24.1\                      184.5                         13 w        Healthy volunteers 18--40 years of age body weight of 45.5--91 kg no known medical conditions not taking prescription medications no chemosensory abnormalities                                                       Affect grid; POMS                                                                                                                                                                              2004
           Placebo: 9 F; 9 M            23.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@B8]    26 F; 26 M\                  21.3\                      120                           One-dose\   Healthy volunteers exclude current use of psychoactive or anticoagulant medication exclude alcohol or drug dependence exclude pregnancy or lactation or current use of ginkgo                                         SoC; SWM; word presentation; picture presentation; mood rating scale; alcohol and caffeine diaries; PRM; SRM; word recall; picture recall; PASAT                                               2005
           19 F; 21 M                   21.2                                                     6 w                                                                                                                                                                                                                                                                                                                                                                                                                              

  [@B39]   120 mg EGb: 84 F; 85 M\      78.6\                      120; 240                      26 w        a diagnosis of dementia of the Alzheimer's type age ≥ 60 years duration of dementia symptoms at least 6 months Modified Hachinski Ischemic Score less than 4 Mini-Mental State Examination (MMSE) score of 10 to 24   ADAS-cog                                                                                                                                                                                       2005
           240 mg EGb: 96 F; 74 M\      78.1\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
           Placebo: 90 F; 84 M          77.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [@B5]    EGb: 22 F; 24 M\             61.2\                      120                           12 w        Healthy volunteers exclude taking cardiovascular, anticoagulant, antidepressant and antianxiety medication exclude any injury impaired cognitive tests                                                                Woodcock-Johnson Psycho-Educational Battery-Revised                                                                                                                                            2006
           Placebo: 21 F; 26 M\         62.2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
           EGb: 54 M\                   29.7\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
           Placebo: 50 M                31.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, Alzheimer's disease; EGb, Ginkgo biloba L. leaf extract; CFF, Critical Flicker Fusion test; CRT, Choice Reaction Time; LARS, Leeds Analogue Rating Scales; POMS, Profile of Mood States; SoC, Stockings of Cambridge; SWM, spatial working memory; PRM, pattern recognition memory; SRM, spatial recognition memory; PASAT, Paced Auditory Serial Addition Task; ADAS-cog, Alzheimer's Disease Assessment Scale.

###### 

The positive results of clinical trials of AD with EGb.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Patients and gender female   Age (years) \[mean(SD)\]      Ginkgo biloba dose (mg/day)   Duration     Inclusion criteria                                                                                                                                           Outcome measures included in research                                                                         Published date
  ------------------------ ---------------------------- ----------------------------- ----------------------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------- ----------------
  [@B47]                   EGb: 8 F; 19 M\              70.7\                         120                           8 w; 12 w    Elderly patients have mild signs of impairment in everyday function on the Crichton Geriatric Rating Scale                                                   Benton Visual Retention Test; Digit Span Test; Psychometric Test Battery                                      1987
                           Placebo: 12 F; 15 M          71.3                                                                                                                                                                                                                                                                                                                                                

  [@B35]                   EGb: 8 F; 4 M\               73.4\                         120                           12 w; 24 w   Age ≥ 50 years Have signs of mild to moderate memory impairment classified by NINCDS-ADRDA                                                                   Folstein Mini-Mental State Examination; Kendrick Battery (p\<;0.05); digit recall task (p\<0.05)              1991
                           Placebo: 12 F; 3 M           78.3                                                                                                                                                                                                                                                                                                                                                

  [@B31]                   EGb: 5 F; 4 M\               68.5\                         240                           12 w         Age 50--80 years Hachinski Ischemic Score ≤ 4 Mild to moderate Alzheimer-type senile dementia Normal CT finding or a diffuse, possibly asymmetric, atrophy   SKT (p\<0.05); Trailmaking test; ADCS                                                                         1997
                           Placebo: 4 F; 5 M            60.6                                                                                                                                                                                                                                                                                                                                                

  [@B25]                   EGb: 65 F; 55 M\             68                            120                           52 w         Age ≥ 45 years A diagnosis of uncomplicated dementia Mini-Mental State Examination score of 9 to 26 Global Deterioration Scale score of 3 to 6               ADAS-cog (p\<0.05); GERRI (p\<0.01)                                                                           1997
                           Placebo: 72 F; 44 M                                                                                                                                                                                                                                                                                                                                                              

  Kanowski et al. (1997)   EGb: 52 F; 27 M\             EGb: 70.2 (F); 69.7 (M)\      240                           24 w         Age ≥ 55 years SKT score of 6 to 18 MMSE score of 13 to 25                                                                                                   CGI (p\<0.05); SKT (p\<0.05); NAB                                                                             1997
                           Placebo: 53 F; 24 M          Placebo: 72.0 (F); 66.4 (M)                                                                                                                                                                                                                                                                                                                         

  [@B37]                   14 F; 22 M                   43.6                          120; 150; 240; 300            2 d          Asymptomatic volunteers Good physical and mental health Free from concomitant medication                                                                     Short-term memory test (p\<0.05); reaction times (p\<0.05)                                                    1999

  [@B22]                   18 F; 2 M                    19.9                          120; 240; 360                 One-dose     Health undergraduate volunteers Free from medication                                                                                                         Speed of attention (p\<0.05); accuracy of attention; quality of memory (p\<0.05); speed of memory (p\<0.05)   2000

  [@B26]                   EGb: 65 F; 55 M\             68                            120                           26 w         Age ≥ 45 years A diagnosis of uncomplicated AD or multi-infarct dementia MMSE score of 9 to 26 Global Deterioration Scale score of 3 to 6                    ADAS-cog (p\<0.05); GERRI (p\<0.01)                                                                           2000
                           Placebo: 72 F; 44 M                                                                                                                                                                                                                                                                                                                                                              

  [@B19]                   EGb: 72 F; 34 M\             72                            240                           24 w         Age ≥ 55 years Suffered from dementia of the Alzheimer's type or multi-infarct dementia SKT score of 6 to 18 MMSE score of 13 to 25                          SKT (p\<0.01); CGI (p\<0.01); ADAS-cog (p\<0.01)                                                              2003
                           Placebo: 70 F; 29 M                                                                                                                                                                                                                                                                                                                                                              

  [@B32]                   EGb: 13 F; 12 M\             66.2\                         160                           24 w         Brief Cognitive Rating Scale score of 3 to 5 Hachinski Ischemic Score \< 4 IQ \> 80                                                                          SKT (p\<0.01); MMSE; CGI (p\<0.01)                                                                            2006
                           Placebo: 16 F; 10 M          69.8                                                                                                                                                                                                                                                                                                                                                

  [@B33]                   EGb: 143 F; 55 M\            65\                           240                           22 w         Age ≥ 50 years SKT score of 9 to 23 MMSE score of 14 to 25 ADAS-cog score of 17 to 35                                                                        NPI (p\<0.01); SKT (p\<0.01); GBS-ADL (p\<0.01); HAMD (p\<0.01)                                               2007
                           Placebo: 142 F; 55 M         63                                                                                                                                                                                                                                                                                                                                                  

  [@B34]                   EGb: 70 F; 34 M\             66\                           240                           22 w         Age ≥ 50 years SKT score of 9 to 23 MMSE score of 14 to 25 ADAS-cog score of 17 to 35 NPI score of 5 to 12                                                   NPI (p\<0.01); SKT (p\<0.01); GBS (p\<0.01)                                                                   2009
                           Placebo: 78 F; 32 M          64                                                                                                                                                                                                                                                                                                                                                  

  [@B15]                   EGb: 139 F; 63 M\            65                            240                           24 w         Age ≥ 50 years Cognitive score \<35 SKT score of 9 to 23 MMSE score of 14 to 25 ADAS-cog score of 17 to 35 NPI score ≥ 5                                     NPI (p\<0.01); SKT (p\<0.01); ADCS-CGIC (p\<0.01)                                                             2011
                           Placebo: 133 F; 69 M                                                                                                                                                                                                                                                                                                                                                             

  [@B11]                   EGb: 139 F; 61 M\            65.1\                         240                           24 w         Age ≥ 50 years Cognitive score \<35 SKT score of 9 to 23 MMSE score of 14 to 25 NPI score ≥ 6                                                                NPI (p\<0.01); SKT (p\<0.01); ADCS-CGIC (p\<0.01)                                                             2012
                           Placebo: 140 F; 62 M         64.9                                                                                                                                                                                                                                                                                                                                                

  [@B16]                   EGb: 109 F; 54 M\            64.9\                         240                           24 w         Age ≥ 50 years Total error score \< 35 SKT score of 9 to 23 MMSE score of 14 to 25 NPI score ≥ 5                                                             NPI (p\<0.05); SKT (p\<0.05); ADCS-CGIC (p\<0.01)                                                             2012
                           Placebo: 111 F; 59 M         64.2                                                                                                                                                                                                                                                                                                                                                

  [@B12]                   EGb: 139 F; 61 M\            65.1\                         240                           24 w         Scored ≤ 35 in the Test for the Early Detection of Dementia with Differentiation from Depression SKT score of 9 to 23 NPI score ≥ 6                          NPI (p\<0.01); SKT (p\<0.01)                                                                                  2016
                           Placebo: 140 F; 62 M         64.9                                                                                                                                                                                                                                                                                                                                                

  [@B36]                   EGb: 69 F; 24 M\             84.4\                         240                           12 m         Age ≥ 80 years MMSE score of 10 to 23 DemTect score ≤ 9 Scheltens index ≥ 2 Fazekas score ≤ 2                                                                MMSE                                                                                                          2019
                           Donepezil: 69 F; 28 M        84.2                                                                                                                                                                                                                                                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SKT, Syndrom Kurz Test; GERRI, Geriatric Evaluation by Relative's Rating Instrument; CGI, Clinical Global Impression; NAB, Nüberger Alters-Beobachtungsskala; GBS-ADL, Gottfries--Bråne--Steen activities-of-daily-living; NPI, Neuropsychiatric Inventory; HAMD, Hamilton Rating.

Scale for Depression; ADCS-CGIC, Alzheimer's Disease Cooperative Study---Clinical Global Impression of Change.

NINCDS-ADRDS, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer\'s Disease and Related Disorders Association; CT, computerized tomography.

Negative Clinical Results on Cognitive Function {#s2}
===============================================

Single-Dose Studies {#s2_1}
-------------------

A clinical study was conducted on the effect of EGb on cognitive function by Subhan in 1984 ([@B44]). Eight healthy female subjects were administered EGb or placebo, and the psychometric scale was tested after 1 h of administration. Only Sternberg technique was significantly improved with 600 mg EGb to placebo, and there was no difference in Critical Flicker Fusion test (CFF), Choice Reaction Time (CRT), and Leeds Analogue Rating Scales (LARS) among those groups. In 1985, Schaffler et al. ([@B38]) showed EGb only improved complex choice reaction time in a clinical study.

Based on Subhan's research, [@B24] designed a clinical study in healthy young female volunteers in 1990. The volunteers received a single dose of EGb (600 mg) or placebo, and a battery of tests were used after dosing. The results indicated that no statistical differences were observed on CFF and CRT. However, the long-term memory was improved with the followed treatment.

In 2002, Kennedy and Scholey collaborated on two clinical trials ([@B23]; [@B40]). In Kennedy's research, 20 healthy young volunteers received ginkgo, ginseng, ginkgo combined with ginseng, and placebo, respectively. The Cognitive Drug Research (CDR) computerized assessment battery and cognitive outcome factors were used for evaluating cognitive function. For CDR battery, a statistical difference was only observed in immediate word recall, numeric working memory, delayed word recalls, and picture recognition reaction time at 6 h after administration. Furthermore, the quality of memory and serial 7s responses was improved at 6 h after administration. However, other test items had no statistical difference between EGb group and placebo. In Scholey's research, the dosage of EGb was adjusted to 120, 240, and 360 mg. In Serial Threes Task, a statistical difference was only observed in EGb group at 4 h after administration. There was no effect on Serial Seven Task at any time point after oral administration.

Long-Term Studies {#s2_2}
-----------------

In 2001, 26 healthy young females and 24 healthy young males were enrolled in a 30-day clinical trial ([@B43]). Then the subjects were assessed on the neuropsychological tests. The tests included the Digit Symbol Substitution Test (DSST), Speed of Comprehension Test (SCT), Symbol Digit Modalities Test (SDMT), Digit Span; Trail Making Test (TMT), Rey Auditory Verbal Learning Test (AVLT), and Inspection Time (IT). The validated battery of tests was employed to evaluate attention, memory, and work performance. The results indicate that Digit Span Backwards, Working Memory Speed, and AVLT were improved in participants after administration, but the effect was not observed on any of the other tests.

In 2003, 214 participants were allocated to one of three treatments (160 mg/day of EGb, 240 mg/day of EGb, and placebo) ([@B7]). All the participants received EGb for 12 weeks, then randomly allocated for their *Ginkgo* treatment or placebo for another 12 weeks. The score for Syndrom Kurz Test (SKT) and Nürnberger Alters Alltagsaktivitäten (NAA; Nuremberg Gerontopsychological Rating Scale for Activities of Daily Living) were not statistically significant after 24 weeks.

In 2004, 20 females and 19 males were supplemented for 13 weeks with 240 mg of EGb, then the alertness and chemosensory function was used to evaluate cognitive function ([@B30]). The results showed that EGb could improve performance on the chemosensory, but was ineffective at taste and smell function. Quality control problems of the EGb tablets may result in ineffectiveness after administration.

In 2005, 52 university students were randomly divided into EGb and placebo group ([@B8]). Another 40 students received EGb and placebo in long-term study. In both experiments, the performances were evaluated through sustained attention, episodic memory, executive function, and completed mood rating scales. Sustained attention and pattern recognition memory were improved after acute ginkgo treatment, but there were no effects on other tests. There were also no effects on any cognitive tests after 6-week treatment.

To determine the clinical efficacy of EGb in AD, outpatients were supplemented for 26-week treatment with EGb or placebo ([@B39]). Finally, 513 outpatients, including 270 females and 243 males, were randomized to receive 120 mg/day of EGb or 240 mg/day of EGb or placebo for 26 weeks. The changes of Alzheimer's Disease Assessment Scale---cognitive subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study---Clinical Global Impression of Change (ADCS-CGIC) between baseline and week 26 were applied for evaluation strategy. There were no significant differences between groups, and the trial did not show efficacy of EGb.

In 2006, Burns et al. published the results of their clinical experiments, which was a 12-week study assessing effects of EGb on cognitive abilities in healthy young (mean age 30.4 years) or older (mean age 61.7 years) adults ([@B5]). The effect of EGb was evaluated by a series of tests, including cognitive abilities test, chronometric test, and subjective well-being. There were no statistically significant differences on any tests in young participants.

Positive Clinical Results on Cognitive Function {#s3}
===============================================

Single-Dose Studies {#s3_1}
-------------------

In 1999, Rigney et al. designed a clinic study to evaluate the effect of EGb ([@B37]). Thirty-one health volunteers randomly received 120 mg of EGb or 240 mg of EGb or placebo. The battery of test consisted of Steinberg Short Term Memory (SSTM), Linear Analogue Rating Scale (LARS), Leeds Sleep Evaluation Questionnaire (LSEQ), Scanning Task (STM), CFF, CRT, SCT, DSST, and Actigraphy. After administration of EGb, there were statistically significant differences in reaction time, motor reaction time, and CFF, and EGb were more pronounced for memory than attention.

In 2000, a study was designed to investigate the effects of acute doses of EGb on cognitive performance ([@B22]). Eighteen female and two male healthy college students (age 19--24 years) received 120, 240, and 360 mg of EGb or placebo. A tailored version of the CDR computerized assessment battery was used for measuring cognitive function as a consequence of ingestion of EGb of placebo. Compared with the placebo, cognitive function was improved in a number of assessment substances. It was noteworthy that a number of tests were performed dose-dependently after acute administration of EGb.

Long-Term Studies {#s3_2}
-----------------

In 1987, outpatients including 20 females and 34 males (mean age 71.3 years) received 120 mg of EGb or placebo for 12 weeks ([@B47]). The test items included cognitive test buttery and automated psychometric test battery. The batteries comprised the following tests: the Benton Visual Retention Test, Immediate Word Recall, Number Matching Task, Rapid Visual Information Processing Task, CRT, DSST, and Word Recognition. To avoid the limitation and the one-sidedness of experimental results, all tests were combined and measured using two different techniques. The results indicated that EGb was superior to placebo in cognitive tests after administration for 12 weeks. The same results were repeated in another clinical trial in 1991 ([@B35]).

In 1997, nine females and nine males, aged 50--80 years and suffering from mild to moderate dementia of the Alzheimer type, were randomly divided into two groups. These patients were treated with a daily dose of 240 mg EGb or placebo for 3 months ([@B31]). The SKT scores, Trailmaking test (ZVT), and ADAS were used to investigate the effect of EGb on the improvement of cognitive function. Among them, there was a significant difference in SKT test between the EGb group and the placebo group, while there was no significant difference in the other two tests. The SKT was particularly sensitive to changes in mild and moderate dementia, but ADAS showed lower sensitivity than SKT. Furthermore, ADAS showed similar trend with SKT scores.

In 1997, Kanowski et al. also evaluated the efficacy of EGb in 156 outpatients who suffered from dementia of the Alzheimer type ([@B20]). Patients were evaluated by Clinical Global Impressions (CGI), SKT, and Nüberger Alters-Beobachtungsskala (NAB), respectively. There were significantly differences between EGb and placebo.

Le Bars et al. published two trials of EGb for dementia in 1997 and 2000 ([@B25]; [@B26]). In 1997, 309 patients were enrolled in the study, and the primary outcome measures included ADAS-cog, Geriatric Evaluation by Relative's Rating Instrument (GERRI), and CGIC. For the ADAS-cog and GERRI, there was a significant change observed in EGb group at the end point, and no difference was demonstrated in the CGIC. The same results were repeated in 2000.

Hoerr et al. reported the benefits of EGb in dementia of AD type in 2003, 2012, and 2016, respectively ([@B19]; [@B11]; [@B12]). In 2003, 205 patients were included in a trial, and the primary outcome measures were SKT, CGI, and NAB. The effects were statistically significant in SKT and CGI. The EGb showed a mild improvement of NAB in treatment group and placebo group, although there was no statistical difference between the groups. In 2012, the Neuropsychiatric Inventory (NPI) was added into the test item in order to investigate the benefit effect of EGb on neuropsychiatric symptoms (NPSs). The dosage of administration and course of treatment referred to the clinical trial in 2003. The results indicated that EGb alleviated NPSs in patients with dementia. The same results were repeated in another clinical trial in 2016.

In 2006, Mazza et al. designed a study to compare the therapeutic effect of EGb and donepezil in patients with AD ([@B32]). The 76 patients were randomly divided into EGb group, donepezil group, and placebo group, respectively. Mini-Mental State Examination (MMSE), SKT, and CGI were important parameters in demonstrating the clinical efficacy of EGb in cognitive performance. Finally, EGb group and donepezil group showed a statistically significant difference compared with placebo. The results confirmed the efficacy of EGb in cognitive performance, comparable with donepezil clinical efficacy.

In 2007 and 2009, two large-scale clinical trials were designed to study the effect of EGb in cognitive performance by Napryeyenko ([@B33]; [@B34]). In 2007, 391 outpatients suffered from AD or vascular dementia (VaD). The patients in EGb group received 240 mg/day of EGb for 22 weeks. The NPI, SKT, and activities-of-daily-living subscale of Gottfries--Bråne--Steen (GBS-ADL) were used to evaluated the clinical efficacy of EGb, and there were significant differences in the test battery. The same results were repeated in another clinical trial in 2009, and EGb was safe and effective in the treatment of mild dementia caused by AD or VaD.

In 2011 and 2012, Ihl published two clinical studies, which were used to confirm the therapeutic effects of EGb on cognitive dysfunction in elder patients suffered from AD ([@B15]; [@B16]). In both researches, more than 400 outpatients were randomly divided into two groups, which were allocated to receive EGb (240 mg/day) or placebo for 24 weeks. In the result, SKT and NPI scores were improved by EGb, all secondary outcome measures were also improved, including ADCS-CGIC, Verbal Fluency Test, and Alzheimer's Disease Activities-of-Daily-Living International Scale (ADL-IS). Furthermore, adverse event rates were not increased in EGb group. Therefore, EGb was significantly superior to placebo in the treatment of dementia with NPSs.

Recently, Rapp compared treatment outcomes to provide the safety and efficacy of EGb ([@B36]). The 189 patients were randomly treated with EGb (240 mg/day) or donepezil (5 or 10 mg/day) for 12 months. There were no significant differences in cognitive decline measured with the MMSE over 12 months, and the last observation carried forward (LOCF) showed a mild favorable effect for EGb 761 over donepezil.

Discussion {#s4}
==========

EGb has been used therapeutically for many years for symptoms such as cognitive decline, memory deterioration, and decreased alertness. In this review, we summarized the clinical studies from 1984 to 2018, aiming to evaluate the effects of EGb on the intervention of cognitive dysfunction. By comparing the above negative and positive results in [**Tables 1**](#T1a){ref-type="table"} and [**2**](#T2){ref-type="table"}, we found several key factors that influenced the results.

###### 

Consensus statements of EGb from the Asian Clinical Expert Group on Neurocognitive Disorders.

  No                                                                                                           Consensus statement                                                        Concrete content
  ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  1                                                                                                            Efficacy of EGb 761^®^ in AD, VaD, and BPSD                                Best practice for the pharmacological treatment as follows:
  AD: AChEI, memantine, EGb                                                                                                                                                               
  VaD: AChEI, memantine, EGb, antiplatelet therapy                                                                                                                                        
  BPSD: ChEI, nonpharmacological treatment, antipsychotics (off-label), memantine, SSRIs, sedatives, and EGb                                                                              
  2                                                                                                            Management of MCI                                                          EGb may be considered for use in patients with MCI
  3                                                                                                            How to use EGb                                                             EGb can be used as a single agent, and allow sufficient time to take effect
  4                                                                                                            The dosage                                                                 EGb at daily dose of 240 mg
  5                                                                                                            Lack of efficacy or intolerance of standard drugs may warrant use of EGb   EGb was recommended to treat AD, VaD, and mixed dementia, when the patients unable to tolerate the side effects of standard treatments
  6                                                                                                            Adjunctive therapies                                                       EGb was one of the key management options adjunctive to standard pharmacological therapy for AD, VaD, and BPSD
  7                                                                                                            Management of comorbidities                                                EGb played an important role in the management of co-morbidities, such as hypertension, in patients with AD, VaD, and BPSD
  8                                                                                                            Does not appear to prevent dementia                                        EGb was not recommended for prevention of dementia
  9                                                                                                            Well tolerated                                                             EGb had a good tolerability profile in the treatment of MCI, AD, VaD, and BPSD
  10                                                                                                           No overall increased bleeding risk                                         EGb appeared to be no overall added risk of bleeding
  11                                                                                                           No significant interaction with anticoagulants or antiplatelet agents      EGb had been demonstrated no significant interaction with anticoagulants and antiplatelet agents

AD, Alzheimer's disease; VaD, vascular dementia; BPSD, behavioral and psychological symptoms of dementia; MCI, mild cognitive impairment; AChEI, acetylcholinesterase inhibitors; SSRIs, Selective Serotonin Reuptake Inhibitors.

Course and Dosage of Administration {#s4_1}
-----------------------------------

Among the 12 negative results, the duration of administration was mostly single or short-term (less than 12 weeks), and only two experiments were conducted for long-term administration (more than 22 weeks). On the other hand, in the positive results, 11 studies were administered for longer than 22 weeks. In Ihl's and Napryeyenko's research, the changes of SKT score and NPI score were obviously observed in 12-week and 24-week. The differences between the EGb group and the placebo group were gradually expressed with the progress of treatment. Therefore, long-term study was more suitable to evaluate the therapeutic effect of EGb on cognitive dysfunction caused by AD.

Among the 11 negative results, 120 mg or less EGb was administered to treat patients in seven studies. However, 10 positive studies allocated to the treatments with 240 mg or more of EGb. Mattes got negative results, but found that the tablets contained only 65% of the expected concentration in re-analysis. Through literature review and analysis, Mattes found that the treatment can achieve better therapeutic effect when the dosage of EGb was more than 240 mg/day. This opinion was also confirmed in Hashiguchi's research.

Inclusion Criteria {#s4_2}
------------------

Through the analysis of negative and positive results, the inclusion criteria play a key role. In the negative studies, nine clinical studies involved healthy young subjects. However, 13 clinical studies involved elder outpatients in positive research. In the meta-analysis published by Lijuan Jiang ([@B17]), EGb was more suitable for the treatment of elderly patients, especially aged 60 to 75 years. Furthermore, several studies have also set strict rules about the inclusion criteria, including the MMSE, SKT, and NPI score.

Outcome Measures {#s4_3}
----------------

Through meta-analysis, Hyde thought that EGb was more suitable for the treatment of patients suffered from AD combined with mental disorder ([@B14]). Hashiguchi further pointed out that SKT score was more applicable to evaluate patients with mild-moderate AD ([@B10]). During recent years, SKT score was used to evaluate the therapeutic effect in positive results.

In 2018, nine countries, including China, Germany, and Singapore, had jointly published a clinical guideline on the treatment of dementia mild cognitive impairment with EGb ([@B18]). In the guideline, several compelling evidences supported the inclusion of EGb as part of the treatment armamentarium for AD or VaD ([**Table 2**](#T2){ref-type="table"}). EGb showed encouraging efficacy in terms of improvement in cognition impairment and mental condition in patients with AD or VaD.

Through analysis and comparison, we consider EGb may be able to improve the cognitive function in patients suffering from mild dementia during administration (more than 24 weeks) and appropriate dosage (240 mg per day). However, there are some limitations in the studies that should be noted. AD is a disease with a long course; the effects of the drug may change over time. According to a recent research, aducanumab was deemed to indicate little chance of treatment efficacy in March 2019 ([@B13]), but the conclusion was overturned with the full 18 months of treatment in October 2019 (<http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials>). In our opinion, most clinical trials of EGb were less than 24 weeks. We suggest that clinical trials with longer treatment are more appropriate to demonstrate the efficacy of EGb. Furthermore, some key biomarkers such as apolipoprotein E4 (*APOE4*) were identified as a single greatest genetic risk factor for sporadic AD in clinical settings ([@B29]; [@B3]; [@B4]). However, *APOE4* was not involved in the study of EGb. Therefore, the relationship between EGb and APOE was still a mystery; it may be a research direction in the future.
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